Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Target Validation, 2010
    VEGF-B - A New Neurotrophic Factor for Treatment for Parkinson's Disease

    Objective/Rationale
    We discovered that the vascular endothelial growth factor, VEGF-B, acts as a natural response of brain cells to a neurotoxin that produces Parkinson’s disease in pre-clinical...

  • Target Validation, 2010
    mTORC1 as a Target for the Treatment of Levodopa-induced Dyskinesia

    Objective/Rationale
    The choreic and dystonic movements, or dyskinesia, which develop in response to prolonged treatment with levodopa, represent one of the major limitations to the current therapy...

  • Target Validation, 2010
    Peroxisome-Proliferator Activated Receptor gamma as a Target for Anti-Dyskinesia Pharmacotherapy

    Objective/Rationale
    We plan to develop new pharmacological approaches to treat levodopa-induced dyskinesia (LID) in a pre-clinical model of Parkinson’s disease (PD). Preliminary data from our...

  • Target Validation, 2010
    Targeting the Unfolded Protein Response (UPR) Transcription Factor XBP-1 to Treat Parkinson's Disease

    Objective/Rationale
    Our general objective is to investigate the role of a specific component of a cellular stress responses linked to organelle damage, the Unfolded Protein Response (UPR), in the...

  • Target Validation, 2010
    Modulation of the Rho Kinase pathway for improvement of regeneration in PD

    Objective/Rationale
    A characteristic feature of Parkinson’s disease is the loss of axons, the long processes of neuronal cells. This loss of axons seems to occur early in the course of the disease...

  • Rapid Response Innovation Awards, 2010
    SNCA Haplotyping in Parkinson's Disease and Multiple System Atrophy

    Objective/Rationale:
    A succinct, lay-oriented statement of the scientific rationale for this project. We have recently shown that genetic variants at the SNCA gene locus, coding for the alpha-synuclein...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.